Recent Posts
- Press Release: New 48-Week Frexalimab Phase 2 Data Support Potential For High Sustained Efficacy In Multiple Sclerosis
- The Siegel Rare Neuroimmune Association Marks 30 Years of Improving Quality of Life for People With Rare Neuroimmune Disorders
- The Language of MS: How Much Does It Matter?
- Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
- Thinking Critically about World Wide Web Resources
- Is it MS or Something Else? updated guide is published to expedite and uncover the answer
- In memoriam: Barry GW Arnason, MD, FAAN
- Positive Phase III results for Genentech’s Ocrevus (ocrelizumab)
- Abstracts for CMSC 2023 Annual Meeting reflect multidisciplinary multiple sclerosis research
- CMSC 2023 Annual Meeting program offers cutting-edge science & clinical skill updates
- (201) 487-1050
- 3 University Plz Dr Ste 116, Hackensack, NJ 07601
- info@mscare.org